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Abstract
The exact pathophysiology of non-alcoholic steatohepatitis (NASH) is not known. Previous studies suggest that dietary
advanced glycation end products (AGEs) can cause oxidative stress in liver. We aim to study the effects of dietary AGEs on
liver health and their possible role in the pathogenesis of NASH. METHODS: Two groups of mice were fed the same diet
except the AGE content varied. One group was fed a high AGE diet and the second group was fed a regular AGE diet. Liver
histology, alanine aminotransferase, aspartate aminotransferase, fasting glucose, fasting insulin, insulin resistance and
glucose tolerance were assessed. RESULTS: Histology revealed that neutrophil infiltration occurred in the livers of the high
AGE group at week 26; steatosis did not accompany liver inflammation. At week 39 livers from both groups exhibited
macro- or micro-steatosis, yet no inflammation was detected. Higher insulin levels were detected in the regular AGE group
at week 26 (P=0.034), compared to the high AGE group. At week 39, the regular AGE group showed higher levels of
alanine aminotransferase (P,0.01) and aspartate aminotransferase (P=0.02) than those of the high AGE group.
CONCLUSIONS: We demonstrate that a high AGE diet can cause liver inflammation in the absence of steatosis. Our results
show that dietary AGEs could play a role in initiating liver inflammation contributing to the disease progression of NASH.
Our observation that the inflammation caused by high AGE alone did not persist suggests interesting future directions to
investigate how AGEs contribute to pro-oxidative and anti-oxidative pathways in the liver.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common
cause of abnormal liver enzymes in the U.S. [1], accounting for a
quarter of all chronic liver diseases [2]. NAFLD is linked to
excessive accumulation of triglyceride (TG) in the liver and
encompasses a broad spectrum of liver pathology, ranging from
steatosis to nonalcoholic steatohepatitis (NASH) with fibrosis that
may progress to liver cirrhosis, portal hypertension, and even
hepatocellular carcinoma. NAFLD occurs in approximately 40–
90% of all obese individuals and 15% of those individuals progress
to NAFLD’s severe form, NASH [3,4,5]. The incidence of
NAFLD and NASH has been steadily increasing as the prevalence
of obesity continues to rise [2]. Currently, NASH is the third most
common indication for liver transplantation in the United States
and is projected to become the most common reason for liver
transplantation in the near future [6].
Evidence from animal models and human studies suggests that
oxidative stress is one of the key factors in the disease progression
of NASH [7,8,9]. Oxidative stress in the liver of NASH patients
could arise from several pathways. One pathway is related to
impaired electron flow through the mitochondrial respiratory
chain (MRC) [10,11]. When normal electron flow is interrupted,
electrons are transferred to oxygen molecules from respiratory
intermediates, generating superoxide anions and hydrogen
peroxide [7,12]. MRC impairment also increases fatty acid
oxidation at peroxisomes and endoplasmic reticulum, resulting
in the production of additional reactive oxygen species (ROS)
[13,14]. In addition, an animal model [15] and a human study
[16] suggest that alcohol produced by obesity-related colonic
microbes can contribute to the elevated ROS production.
Advanced glycation end products (AGEs) are potent trigger for
ROS production in NASH livers [17]. AGEs are a heterogeneous
group of molecules formed from the nonenzymatic reaction of
reducing sugars with free amino groups of proteins, lipids and/or
nucleic acids. AGEs may be formed exogenously by heating sugars
with fats or proteins (Maillard reaction), from tobacco smoke, or
endogenously through normal metabolism and aging [18,19,20].
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www.In vitro experiments with a hepatic stellate cell line LI90
demonstrated that AGEs increase ROS production by NADPH
oxidase and MRC [21]. This was confirmed by an in vivo study, in
which mice fed a high AGE diet had lower levels of reduced
glutathione/oxidized glutathione ratio and higher levels of 8-
isoprostanes (lipid peroxidation products) than mice fed a low
AGE diet [22]. To understand the effects of AGEs on liver and
their possible role in the pathogenesis of NASH, we fed diets
containing different amounts of AGEs to mice. Examination of the
liver morphology and function revealed that a diet high in AGEs
could induce inflammation independent of liver fat deposition.
Materials and Methods
Animals
All procedures involving mice were reviewed and approved by
the Institutional Animal Care and Use Committee of University at
Buffalo. Four week old C57BL/6NHsd male mice were purchased
from Harlan Laboratories (Indianapolis, IN). These mice were
individually caged and provided free access to water. Mice were
divided into two groups: 1) regular AGE group, mice were fed with
TestDiet 58G7 (TestDiet, Richmond, IN); 2) high AGE group,
mice were fed with TestDiet 58G7 autoclaved at 120uC for
15 min, following a published method for the preparation of high
AGE diet [23]. To monitor the growth of experimental groups,
two mice fed ad lib with standard mouse chow (Teklad Global 18%
Protein Rodent Diet, Harlan Laboratories) were used as reference
animals. Fat contributed 12% of calories in TestDiet 58G7,
compared to 18% in the standard mouse chow Teklad Global
18% Protein Rodent Diet. All mice in the study received the same
calorie per gram body weight on a weekly basis.
Measurement of AGEs
The concentrations of the major types of AGEs, carboxymethyl
lysine and methylglyoxal, in mouse diets were determined by
enzyme-linked immunosorbent assays as described previously [23].
Histopathology
Five mice from each group were sacrificed on weeks 13, 26 and
39. Whole body perfusion was performed via left ventricle with
oxygenated phosphate buffered saline supplemented with 1mM
CaCl2 and 1mM MgCl2. Liver pieces of ,5mm in all dimensions
were taken from the mice and fixed in 4% formaldehyde for
15 min. The liver pieces were then sequentially equilibrated in
30% sucrose, 15% sucrose/50% OCT (Optimal Cutting Tem-
perature medium, Sakura Finetek, Torrance, CA), and 100%
OCT. The liver pieces were frozen in OCT before 10 mm sections
were cut with a cryostat. The sections were stained with
hematoxylin/eosin (H&E) or oil red O and visualized by light
microscopy. A pathologist (R. K.) assessed each slide for
steatosis, inflammation and fibrosis.
Glucose, Insulin, Alanine Aminotransferase (ALT) and
Aspartate Aminotransferase (AST) Measurements
Animals were fasted overnight before blood was collected via
the submandibular vein with a sterile 5 mm point golden rod
lancet (Medipoint, Mineola, NY). Glucose levels were measured
using a FreeStyle Lite glucometer (Abbott Laboratories, Abbott
Park, IL). Each reported value was the average of two readings.
The remaining blood samples were incubated at 37uC for 40 min
followed by centrifugation at 15,000g for 20 min at room
temperature. Collected serum was aliquoted and stored at
280uC before further analysis. Insulin levels were determined
with ELISA kits purchased from Mercodia (Uppsala, Sweden)
following manufacturer’s instructions. Insulin resistance (IR) was
calculated using the homeostasis model assessment (HOMA)
method (fasting blood glucose (mmol/L) x fasting serum insulin
(mU/L)/22.5 [24]. Serum ALT and AST activities were measured
with ALT Enzymatic Assay Kits and AST Enzymatic Assay Kits
(Bioo Scientific, Austin, TX) following product manuals.
Glucose Tolerance Test
Intraperitoneal glucose tolerance tests (IPGTT) were performed
as described previously [25]. Briefly, glucose (2 mg/g body weight)
was delivered intraperitoneally to each animal after an overnight
fast. Glucose readings were taken from the tail immediately before
and several times after glucose injection as specified in Figure
legend.
Statistics
All analysis for statistically significant differences was performed
with Student’s t test with a two-tailed distribution. P values #0.05
were considered significant.
Results
AGEs and Animals
To evaluate the effect of dietary AGE on mouse liver, a high
AGE mouse diet was prepared by high temperature treatment.
The AGE contents in the diets were measured by ELISAs with
antibodies against two major types of AGE molecules, carbox-
ymethyl lysine and methylglyoxal, respectively (Table 1). These
measurements indicated that the high AGE diet had an AGE
content about three times that of the regular AGE diet.
Two groups of mice were fed either a high AGE diet or a
regular AGE diet. These two groups showed similar growth curves
over the 39 weeks of the study; no significant difference was
observed at any time point throughout the study (Figure 1). The
growth curves of these two groups were also similar to that of the
reference animals fed with regular mouse chow (data not shown).
Histology
Five animals from each group were sacrificed at week 13, 26,
and 39 to examine the possible effect of AGE on mouse livers.
Cryosections of liver from each animal were stained with H&E
and oil red O. Examination of the liver histology of all animals
from the high AGE group and the regular AGE group showed no
evidence of steatosis or inflammation at week 13 (data not shown).
However, abnormalities were detected at week 26. Liver sections
from two of the five high AGE-fed mice exhibited extensive
macro- or micro-vesicular steatosis as indicated by oil red O
staining (Figure 2A). More importantly, inflammatory foci were
evident in the liver sections of two mice in the high AGE group.
The inflammation observed was mild; no evidence of liver
damage, regeneration or fibrosis was observed. It is noteworthy
that livers with steatosis did not have inflammatory foci, while
Table 1. AGE content in mouse diets.
Mouse chow CML
a (U/g) MG
b (nmol/g)
TestDiet 58G7 6064961147
c 1107639
High-heat treated TestDiet 58G7 197305617441 3899691
aCarboxymethyl Lysine.
bMethylglyoxal.
cSample mean6standard deviation.
doi:10.1371/journal.pone.0035143.t001
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from the regular AGE fed group exhibited steatosis at week 26,
but no inflammatory focus was observed in the livers of this group
(Figure 2B). It is striking that all liver sections from both groups
exhibited extensive macro- or micro-vesicular steatosis at week 39
(Figure 3A, B), despite the fact that both diets are of low fat content
(contributing 12% calorie). No inflammatory focus was observed
in any section from either group at week 39 (Figure 3A, B).
Liver Function Tests
Serum ALT and AST levels were measured to evaluate
hepatocellular damage. Normal ALT and AST values were
observed in all animals at week 5 of dietary treatment (Figure 4A
& B). At week 26, the ALT levels remained normal in all animals
(Figure 4A); however, marked elevation of AST levels were
observed in both groups (Figure 4B). At week 39, ALT and AST
levels from both groups were elevated (Figure 3A & B). Both ALT
and AST were significantly higher in the regular AGE group
compared to the high AGE group (p,0.01 and p=0.02,
respectively). These results indicate that liver injury occurred by
39 weeks in these animals and was more pronounced in those fed
the regular AGE diet.
Glucose Metabolism
Because fat deposition in parenchymal cells (Figure 3 A & B) can
contribute to abnormal metabolism, fasting insulin, glucose and
insulin resistance in both groups were examined. Fasting insulin
levels were higher in the regular AGE group compared to the high
AGE group (P=0.034) at week 26 (Figure 5 A). However, fasting
glucose and HOMA-IR were comparable between the two groups
(Figure 5B & C). At week 39, no significant difference was
observed for fasting insulin, glucose or IR-HOMA between mice
fed with different amounts of dietary AGE (Figure 5 A, B and C).
To further examine glucose homeostasis, intraperitoneal glucose
tolerance tests (IPGTT) were performed at week 39. All animals
exhibited glucose intolerance as evidenced by persistent hypergly-
cemia 2 h after intraperitoneal glucose injection (Figure 6). No
significant difference in glucose was observed between the high
AGE fed mouse group and the regular AGE fed mouse group at
each time point tested (15 min, 30 min, 1 h and 2 h).
Discussion
Most fatty livers do not develop liver inflammation [26], a
hallmark of NASH. Factors contributing to the development of
liver inflammation remain undefined. Our results show that
dietary AGEs can cause liver inflammation and therefore
contribute to the pathogenesis of NASH. Inflammatory foci were
detected in mouse livers at week 26 when fed with a high AGE
diet, while mice fed the regular AGE diet remained free from liver
inflammation throughout the length of the 39 week study. This is
consistent with the well-established concept that dietary AGE can
initiate oxidative stress via AGE receptors expressed in liver cells
[21,22]. The fact that steatosis was not a characteristic of these
inflammed livers suggests that dietary AGE alone is sufficient to
cause liver inflammation, independent of steatosis. Therefore, our
data suggest that dietary AGEs can play a role in initiating
inflammation contributing to the disease progression of NASH.
Our results are of immediate practical value for current and
prospective NASH patients as AGEs are often major components
of processed food [27], and one study demonstrated that serum
AGE levels in NASH patients were higher than those of patients
with steatosis and healthy controls [28].
On the other hand, some mice at week 26 and all animals at
week 39 developed macro- or micro-vesicular steatosis, and all
animals exhibited glucose intolerance at week 39, but there was no
progression to liver inflammation with these fatty livers. These
results recall the observation that ob/ob mice develop steatosis and
insulin resistance [29] but not liver inflammation [30]. Our animal
studies mirror the epidemiology of human NASH in that most
people who have steatosis do not show progression to liver
inflammation [26]. However, we were surprised that no
inflammation was detected in any of the fatty livers in the high
AGE fed group at week 39. It is broadly believed that steatosis
sensitizes the liver to secondary insults in the development of liver
inflammation and further liver complications [31]. As an agent to
induce oxidative stress, dietary AGE could be one of the secondary
insults. Yet, mild inflammation was detected only at week 26 but
not at week 39 in the high AGE fed mice indicating that mild
inflammation could resolve over time despite the appearance of
steatosis in the presence of continued consumption of a high AGE
diet. One possible explanation is that anti-oxidative mechanisms
were activated to fight against the stress generated by the high
AGE diet. Although AGEs induce oxidative stress via the cognate
receptor RAGE, one study suggested that AGEs also induce
glutathione S-transferase activity to function as an antioxidant
[32]. This also provides a reasonable explanation for our
observation that mice fed a high AGE diet exhibited significantly
lower serum ALT and AST activities at week 39 than those on a
regular AGE diet. We speculate that mechanisms may exist to
silence the RAGE mediated pathway while maintaining the
beneficial effects of AGE. We currently are examining known anti-
oxidative pathways in these animals with the goal of identifying the
mechanism(s) that protect the animals from oxidative stress. Our
approach may reveal the molecular mechanism for how AGEs
activate pro-oxidative but not anti-oxidative reactions.
Another possible explanation for this self-resolving inflamma-
tion is the low fat content in the diets of our study. One
outstanding observation in our study was that fasting glucose,
insulin, IR-HOMA and glucose tolerance were similar between
high AGE and regular AGE fed mouse groups. This is in contrast
Figure 1. Growth curves. Body weights of mice fed with a high AGE
diet or a regular AGE diet were plotted. Error bars represent standard
deviations with plus direction for the high AGE group and the minus
direction for the regular AGE group.
doi:10.1371/journal.pone.0035143.g001
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that a high AGE diet caused a , 5 fold increase in fasting insulin
level and significant glucose intolerance as compared to regular
AGE fed animals. Sando et al. also found that plasma 8-
isoprostane, a measurement of systemic oxidant stress, were
significantly elevated in the high AGE diet fed animals. One major
difference between our experimental approaches is that high fat
diets were used in the study of Sandu et al., while low fat diets were
used in our study. Therefore, we speculate that dietary fat content
differences contribute to the conflicting results. Perhaps, high AGE
diet exacerbates the metabolic defect precipitated by a high fat
diet. As such, it is of great interest to test whether low fat diets
protect hepatocytes from the adverse effects of AGEs and
prevented persistent liver inflammation. Another important
question stemming from this discrepancy is whether a high AGE
diet facilitates the development of liver inflammation on the
background of a high fat diet and/or obese mouse model (db/db
or ob/ob).
AGEs have been implicated in the pathogenesis of various
diseases including diabetes [33], atherosclerosis [34], Alzheimer’s
disease [35], and melanoma growth and metastasis [36,37].
Vlassara and colleagues reported that a high AGE diet induces
pro-inflammatory cytokines in diabetic patients [38], but ethical
considerations make it impossible to obtain direct evidence that
human liver inflammation is induced by a high AGE diet. Because
we show neutrophil infiltration, our mouse study has unique value
in supporting a causative link between AGE and liver inflamma-
tion. Chuyen and colleagues examined the effect of dietary AGE
on the liver enzymes superoxide dismutase and glutathione-S-
transferase in a rat model [39]. They reported no adverse effect of
AGEs. The discrepancy between their study and ours may be
explained by the fact that their rat study only lasted for 11 weeks
and the authors did not examine the liver histology.
One of the striking and important aspects of our study is its
length. For example, if this study had been terminated after a short
period of time, as other studies of diet and liver injury have been,
our observation that resolution of inflammation is possible would
Figure 2. Liver histology of mice fed with a high AGE diet or a regular AGE diet for 26 weeks. Mice on the high AGE diet (A) or the regular
AGE diet (B) for 26 weeks were whole-body perfused before liver collection. Cryosections of the livers were stained with H&E, or oil red O (ORO),
respectively. Each row has the typical images of H&E and ORO staining of the same liver.
doi:10.1371/journal.pone.0035143.g002
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ing of mechanisms that could be used to mitigate harmful effects of
diet on the liver.
In this study, liver inflammation occurred before steatosis in the
high AGE diet group. This phenomenon may add to the debate
on whether steatosis is a consequence of liver inflammation or vice
Figure 3. Liver histology of mice fed with a high AGE diet or a regular AGE diet for 39 weeks. Mice on high AGE diet (A) or regular AGE
diet (B) for 39 weeks were whole-body perfused before liver collection. Cryosections of the livers were stained with H&E, or oil red O (ORO),
respectively. Each row has the typical images of H&E and ORO staining of the same liver.
doi:10.1371/journal.pone.0035143.g003
Figure 4. Measurement of serum ALT and AST. Sera were obtained from mice fed with a high AGE diet or a regular AGE diet. ALT (A) and AST
(B) enzymatic activities were measured as specified in Materials and Methods. Error bars represent standard deviations (n=5 for both groups).
doi:10.1371/journal.pone.0035143.g004
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observed between high and low AGE diet groups at week 39, cell
type specific differences might have existed between two groups at
some time points during the length of this study. Further
investigation on individual liver cell types may reveal possible link
between inflammation and steatosis and other aspects of the
NASH pathophysiology.
In summary, we demonstrate that a high AGE diet causes liver
inflammation in the absence of steatosis. This finding is relevant to
patients at high risk for NASH and other liver injuries. Our
observation that the inflammation caused by high dietary AGE
alone did not persist suggests interesting future directions to
investigate how AGE induced pro-oxidative pathways are
regulated and how they may be down-regulated by AGE-induced
anti-oxidative pathway. The animal model we developed is a
valuable platform on which a therapeutic and preventive agent
against the adverse effects of AGEs could be identified and tested.
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